PTC THERAPEUTICS INC (PTCT:NASDAQ)
$64.7 2.14 (3.4207%)
Analysed PTC THERAPEUTICS INC (PTCT:NASDAQ) News Sources
PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program
12-08-2026
yahoo.com
PTC takes a chance on Sangamo’s Fabry disease gene therapy
13-08-2026
biopharmadive.com
PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal
16-08-2026
marketbeat.com
Wells Fargo Sees Up to 52% Upside in 2 Stocks
17-08-2026
yahoo.com
PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile
24-08-2026
yahoo.com
PTC Therapeutics to Participate in Upcoming Investor Conferences
27-08-2026
yahoo.com
PTC Therapeutics (PTCT) Could Be 36% Undervalued Following Pipeline Progress
20-09-2026
yahoo.com
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
21-09-2026
yahoo.com
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
25-09-2026
yahoo.com
2026 Philadelphia ORBIE Awards Honor Top Technology and Security Executives in Philadelphia
28-09-2026
yahoo.com
What is the current price of PTC THERAPEUTICS INC (PTCT:NASDAQ)?
The current price of PTC THERAPEUTICS INC (PTCT:NASDAQ) is $64.7.
PTC THERAPEUTICS INC (PTCT:NASDAQ) absolute price change since previous trading day?
The absolute price change of PTC THERAPEUTICS INC (PTCT:NASDAQ) since the previous trading day is $2.14.
PTC THERAPEUTICS INC (PTCT:NASDAQ) percentage price change since previous trading day?
The percentage price change of PTC THERAPEUTICS INC (PTCT:NASDAQ) since the previous trading day is 3.4207%.
What is the most recent average sentiment score for PTC THERAPEUTICS INC (PTCT:NASDAQ)?
The most recent average sentiment score for PTC THERAPEUTICS INC (PTCT:NASDAQ) is 82 out of 100.
What is the most recent average sentiment for PTC THERAPEUTICS INC (PTCT:NASDAQ)?
The most recent sentiment for PTC THERAPEUTICS INC (PTCT:NASDAQ) is .
SEC-8K** Filing Available For PTC THERAPEUTICS INC (PTCT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.